Status:
COMPLETED
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
Lead Sponsor:
Pfizer
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and...
Eligibility Criteria
Inclusion
- Chinese patients
- Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints
- Active plaque psoriasis at screening
- Inadequate response to at least one conventional synthetic DMARD
Exclusion
- Non-plaque forms of psoriasis (with exception of nail psoriasis)
- History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA
Key Trial Info
Start Date :
August 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2021
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT03486457
Start Date
August 10 2018
End Date
April 28 2021
Last Update
February 8 2024
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China, 233004
2
Anhui Provincial Hospital
Hefei, Anhui, China, 230001
3
The First Affiliated Hospital of Anhui Medical University/Rheumatology Department
Hefei, Anhui, China, 230022
4
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034